Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IBU vs TYLENOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, thereby reducing inflammation, pain, and fever.
Acetaminophen is a centrally acting analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, preferentially COX-2, and modulation of descending serotonergic pathways.
Rheumatoid arthritis,Osteoarthritis,Mild to moderate pain,Dysmenorrhea,Fever,Patent ductus arteriosus closure in neonates (off-label)
Mild to moderate pain (FDA-approved),Fever (FDA-approved),Osteoarthritis pain (off-label),Patent ductus arteriosus in neonates (off-label IV formulation)
200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day. For OTC use: 200-400 mg every 4-6 hours; max 1200 mg/day.
650 mg orally every 4-6 hours or 1000 mg orally every 6 hours; maximum 4000 mg per day.
Terminal elimination half-life: 2-4 hours in adults; prolonged in neonates (30 hours) and elderly (up to 6 hours). No accumulation with recommended dosing due to short t½.
Terminal elimination half-life is 2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment
Hepatic metabolism primarily via CYP2C9 to inactive metabolites; minor pathways include CYP2C8.
Primarily hepatic via conjugation with glucuronide (UGT1A1, UGT1A6, UGT1A9) and sulfate (SULT1A1, SULT1A3); minor oxidation by CYP2E1, CYP1A2, and CYP3A4 to N-acetyl-p-benzoquinone imine (NAPQI), which is detoxified by glutathione.
Renal (90% as conjugated metabolites, 10% unchanged), biliary/fecal (minor, <5%)
Renal excretion of conjugated metabolites (glucuronide and sulfate conjugates) accounts for >90% of elimination; less than 5% excreted unchanged; minor biliary/fecal elimination (<5%)
99% bound primarily to albumin
10-25% bound to plasma proteins (primarily albumin); binding is minimal and not clinically significant
0.1-0.2 L/kg, indicating low tissue distribution; predominantly confined to plasma and extracellular fluid.
0.8-1.0 L/kg; low Vd indicates limited extravascular distribution, consistent with limited CNS penetration
Oral: 80-100% (immediate-release), 70-90% (extended-release); Topical: approximately 5-10% systemic absorption; Intravenous: 100%.
Oral: 60-90% (first-pass hepatic metabolism reduces bioavailability); Rectal: 70-90%; Intravenous: 100%
Cr Cl >30 m L/min: no adjustment. Cr Cl 10-30 m L/min: 200 mg every 12 hours; avoid if Cr Cl <10 m L/min.
GFR 10-50 m L/min: Administer every 6 hours. GFR <10 m L/min: Administer every 8 hours.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or avoid. Child-Pugh C: contraindicated due to risk of hepatotoxicity.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%; maximum 2000 mg/day. Child-Pugh C: Reduce dose by 75%; maximum 1000 mg/day.
6 months to 12 years: 5-10 mg/kg/dose every 6-8 hours; max 40 mg/kg/day. For juvenile idiopathic arthritis: 30-40 mg/kg/day divided every 6-8 hours; max 50 mg/kg/day.
10-15 mg/kg orally every 4-6 hours; maximum 75 mg/kg/day or 5 doses per day.
Initiate at lowest effective dose; consider 200 mg every 8-12 hours; monitor renal function and GI bleeding risk.
Reduce dose by 25-50% in frail elderly; maximum 3000 mg/day due to increased hepatotoxicity risk.
NSAIDs cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk may increase with duration of use. Contraindicated for treatment of peri-operative pain in coronary artery bypass graft (CABG) surgery.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen in doses exceeding 4000 mg per day. The risk of acute liver failure may be higher in individuals with underlying liver disease and in those who consume alcohol chronically.
Cardiovascular thrombotic events,Gastrointestinal bleeding, ulceration, and perforation,Hypertension,Heart failure exacerbation,Renal toxicity,Anaphylactic reactions,Serious skin reactions (e.g., Stevens-Johnson syndrome),Hematologic effects (anemia, bleeding)
Hepatotoxicity: Risk increases with doses > 4000 mg/day, chronic alcohol use, or preexisting liver disease.,Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis.,Hypersensitivity: Rare anaphylaxis.
History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Peri-operative pain in CABG surgery,Active gastrointestinal bleeding,Advanced renal disease,Third trimester of pregnancy
Hypersensitivity to acetaminophen,Severe hepatic impairment (e.g., active liver disease)
Ibuprofen can increase the risk of stomach bleeding when taken with alcohol. No specific food restrictions, but taking with food or milk can reduce GI irritation.
No significant food interactions. Alcohol consumption increases risk of hepatotoxicity; avoid concurrent use. High-carbohydrate meals may slightly delay absorption.
First and second trimester: Increased risk of miscarriage and congenital malformations (particularly cardiac defects) associated with NSAID use. Third trimester: Known risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment; contraindicated after 30 weeks gestation.
Acetaminophen crosses the placenta. First trimester: no increased risk of major malformations in prospective studies; retrospective studies show possible association with gastroschisis and neural tube defects but confounding by indication is likely. Second and third trimesters: no consistent evidence of adverse fetal effects; chronic high doses may cause maternal hepatotoxicity with secondary fetal effects. Avoid prolonged high-dose therapy.
Ibuprofen is excreted into breast milk in low concentrations (M/P ratio approximately 0.01-0.03). Considered compatible with breastfeeding by the American Academy of Pediatrics; use lowest effective dose for shortest duration.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio approximately 0.9; peak milk concentration 10-15 µg/m L after 1g oral dose). Relative infant dose is <2% of maternal weight-adjusted dose. Considered compatible with breastfeeding; monitor infant for rash or drowsiness.
Increased plasma volume and renal clearance in pregnancy may reduce drug levels; however, no standard dose adjustment recommended. Use lowest effective dose, avoid in third trimester.
Increased clearance in pregnancy may reduce AUC by 25-30%; recommend standard dosing (500-1000mg every 4-6 hours, max 3000-4000mg/day). No dosage adjustment typically needed. Avoid extended-release formulations due to variable absorption.
Ibuprofen is a nonselective COX inhibitor with anti-inflammatory, analgesic, and antipyretic effects. Avoid in patients with aspirin allergy, active peptic ulcer, or severe renal impairment. Use lowest effective dose for shortest duration to minimize GI and cardiovascular risks. Not recommended in patients with advanced chronic kidney disease (e GFR <30 m L/min/1.73 m²). For acute pain, ibuprofen 200-400 mg every 6 hours PRN. Monitor for signs of GI bleeding, hypertension, and fluid retention.
Acetaminophen has minimal anti-inflammatory effect; prefer NSAIDs for inflammation. Max daily dose 3 g (or 2 g in at-risk patients). N-acetylcysteine is antidote for overdose; administer if serum level above nomogram line. Avoid in severe hepatic impairment. Intravenous formulation available for acute pain. Onset of action 30-60 min, duration 4-6 h. No effect on platelets or GI mucosa.
Take with food or milk to reduce stomach upset.,Do not exceed 1200 mg per day unless directed by your doctor.,Avoid alcohol while taking this medication.,Stop use and seek medical help if you experience chest pain, weakness, slurred speech, or signs of stomach bleeding (black/tarry stools, vomit that looks like coffee grounds).,Do not take with other NSAIDs or aspirin without consulting your healthcare provider.
Do not exceed 3 g (3000 mg) per day from all products.,Check all over-the-counter medications for acetaminophen content.,Do not take with alcohol or if you have liver disease.,Seek immediate medical attention if overdose is suspected.,May be taken with food if GI upset occurs (though rare).
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IBU vs TYLENOL, answered by our medical review team.
IBU is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, thereby reducing inflammation, pain, and fever.. TYLENOL is a Analgesic (non-opioid) that works by Acetaminophen is a centrally acting analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, preferentially COX-2, and modulation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IBU and TYLENOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IBU is: 200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day. For OTC use: 200-400 mg every 4-6 hours; max 1200 mg/day.. The standard adult dose of TYLENOL is: 650 mg orally every 4-6 hours or 1000 mg orally every 6 hours; maximum 4000 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IBU and TYLENOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IBU is classified as Category C. First and second trimester: Increased risk of miscarriage and congenital malformations (particularly cardiac defects) associated with NSAID use. Third trimester: Known risk of prem. TYLENOL is classified as Category C. Acetaminophen crosses the placenta. First trimester: no increased risk of major malformations in prospective studies; retrospective studies show possible association with gastrosch. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.